The Discounted Cash Flow (DCF) valuation of Protagonist Therapeutics Inc (PTGX) is 43.51 USD. With the latest stock price at 53.00 USD, the upside of Protagonist Therapeutics Inc based on DCF is -17.9%.
Based on the latest price of 53.00 USD and our DCF valuation, Protagonist Therapeutics Inc (PTGX) is a sell. selling PTGX stocks now will result in a potential gain of 17.9%.
| Range | Selected | |
| WACC / Discount Rate | 5.8% - 7.5% | 6.6% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 26.83 - 141.57 | 43.51 |
| Upside | -49.4% - 167.1% | -17.9% |